Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma.

BACKGROUND

Thymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in inhibiting tumor growth and metastasis, suggesting potential as an adjunctive therapy in this challenging clinical setting.

OBJECTIVE

To evaluate the efficacy and safety of Anlotinib as a potential treatment option for thymic carcinoma post-chemotherapy failure, assessing its impact on tumor progression and patient survival outcomes.

CASE PRESENTATION: A 46-year-old female presented with a left supraclavicular mass persisting for one month. Percutaneous needle biopsy of the left mediastinal mass confirmed thymic carcinoma, specifically lowly differentiated squamous cell carcinoma.

MANAGEMENT: The patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin. Notably, fourth-line therapy with Anlotinib monotherapy resulted in a progression-free survival of 10 months.

OUTCOME: Anlotinib emerges as a potential therapeutic option for thymic carcinoma post-chemotherapy failure. However, further validation through preclinical investigations and clinical trials is warranted.

CONCLUSION

Despite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma.

KEYWORDS: thymic carcinoma, anti-angiogenic drugs, Anlotinib, progression-free survival, neovascularization inhibition, metastasis suppression.